| This short report uses data collected from GP practices alongside the National Diabetes Audit (NDA) for the period January 2020 to March 2021 inclusive. This report is for England only (NHS Digital)
Effective 25 October 2021 Forxiga (dapagliflozin) 5mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus (T1DM) and should no longer be used in this population. This is based on Astra Zeneca’s decision to remove the T1DM indication for dapagliflozin 5mg download guidance (European Medicines Agency)
The analysis of data from the LEADER trial demonstrated that higher rates of NSHEs were associated with both a higher risk of severe hypoglycaemia and adverse cardiovascular outcomes in individuals with type 2 diabetes (Diabetologia)
A unified nomenclature concerning the distinction between disease management programs and CCM-based programs should be aimed for. Similarly, homogeneous quality standards and a Europe-wide evaluation strategy would be necessary to identify best practice models and to provide better care for the steadily growing number of chronically multimorbid patients (Journal of Diabetes Research)
This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise (Journal of Diabetes Research)
Use of SGLT2 inhibitors vs GLP-1-receptor-agonists was associated with a similar risk of heart failure and lower risk of serious renal events while use of GLP-1-receptor-agonists vs SGLT2 inhibitors was associated with a slightly lower risk of MACE. In as-treated analyses, the associations with MACE and serious renal events increased in magnitude and the HR for heart failure tended towards a protective association for SGLT2 inhibitors (Diabetes, Obesity and Metabolism)
The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes (Cardiovascular Diabetology)
Deintensifying type 2 diabetes care can include deprescribing and reducing diabetes-specific assessments that no longer improve quality of life of older adults (BMJ)
In a new sub-analysis of the landmark EMPEROR-Preserved® phase III trial, Jardiance reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline (Boehringer Ingelheim and Eli Lilly)
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo (Novo Nordisk)
GMI may better reflect glycemic control than HbA1c in early pregnancy (Diabetes Technology and Therapeutics)
| 
